ArticleBMC psychiatry2025
CATATOnia treatment with transcranial direct current electrostimulation: protocol of a randomised, double-blind, placebo-controlled bicentric superiority study (CATATOES).
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06139432 (Catatonia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Catatonia: Effectiveness of Transcranial Direct Current Electrostimulation (CATATOES)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundCatatonia is a severe psychomotor syndrome with high morbidity and mortality. Lorazepam and electroconvulsive therapy (ECT) are the main recommended treatments. Lorazepam-resistant catatonia accounts for about 30% of cases, particularly in neurodevelopmental disorders. ECT is crucial in these situations but faces challenges of tolerability and accessibility. Transcranial direct current stimulation (tDCS), a promising intervention, is emerging as a non-invasive, cost-effective neurostimulation tool and has demonstrated efficacy and safety in case reports and small series of catatonic patients (N < 10). The CATATOES study aims to assess the efficacy and safety of tDCS using a randomised, double-blind, placebo-controlled, bicentric superiority trial involving 70 patients with catatonia. Secondary objectives aim to highlight the mechanism of action of tDCS and to explore the pathophysiology of catatonia.
methodsSeventy participants with lorazepam-resistant catatonia will undergo 20 sessions of active or sham tDCS, administered twice daily at two mA for 20 min, with anodal stimulation in the left dorsolateral prefrontal cortex (DLPFC) and cathodal stimulation in the left temporoparietal junction (TPJ). In addition to daily clinical assessment, patients will undergo (i) structural, functional and diffusion magnetic resonance imaging (MRI), (ii) 64-channel resting state electroencephalogram (EEG), and (iii) blood test with inflammatory, neurogenesis and genetic markers, before, during and after the treatment course. DISCUSSION: Catatonia is in critical need of therapeutic improvement. We anticipate that this study will pave the way for the routine use of tDCS in the treatment of lorazepam-resistant catatonia, ultimately contributing to a reduction of morbidity, mortality, and associated costs of catatonia. ClinicalTrials.gov Identifier NCT06139432; Registration date 11/24/2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.